NEW YORK, July 14 — The figure that matters: 200. That is the number of peer-reviewed papers Dr. Nir Barzilai has published over his career, a body of work that has placed him at the center of longevity research. Here is the bottom line: Barzilai, an Israeli-American geneticist and professor at the Albert Einstein College of Medicine in New York City, directs the Institute for Aging Research at Einstein.
He is the lead investigator of the TAME trial — Targeting Aging with Metformin — which began in 2016. The trial’s premise is straightforward: test whether metformin, a common diabetes drug, can delay the onset of age-related diseases in healthy older adults.
The Centenarian Blueprint
By the numbers, Barzilai’s LonGenity study, which began in 2008, has been a cornerstone of his work. It examines Ashkenazi Jewish centenarians, defined as those aged 95 and older, to identify the genetic factors that allow them to live exceptionally long lives. Investors will note that this population is genetically homogeneous, making it easier to spot meaningful variants.
In 2003, Barzilai’s team published a study in the Journal of the American Medical Association (JAMA) that delivered a clear finding: centenarians and their offspring have higher levels of HDL cholesterol — the so-called “good” cholesterol — and lower rates of cardiovascular disease. That study provided an early, data-driven clue that longevity may be inherited through specific biological pathways, not just lifestyle.
From Israel to the Bronx
Barzilai was born in 1955 in Israel. He earned his MD from the Technion-Israel Institute of Technology in 1980 and later completed a fellowship at the University of California, San Francisco. His career has spanned continents, but his base of operations has been the Albert Einstein College of Medicine in New York, where he has built a research program focused on the biology of aging.
In 2018, he co-authored the book “Age Later: Health Span, Life Span, and the New Science of Longevity.” The title captures a key distinction in his work: health span — the years of life spent in good health — versus life span, the total number of years lived.
What to Watch Next
The TAME trial remains the most closely watched project in Barzilai’s portfolio. If it succeeds, it could reshape how regulators and physicians think about aging itself — not as an inevitable decline but as a treatable condition. The data from the LonGenity study continues to be mined for genetic targets that might be translated into therapies.
The bottom line: Barzilai’s research has built a bridge between population genetics and clinical trials, one that may eventually change how medicine approaches the aging process. Consult your doctor for medical advice.
